Share Issue/Capital Change • Dec 29, 2020
Share Issue/Capital Change
Open in ViewerOpens in native device viewer
Total of 2,013 new share subscriptions based on the company's 2015C stock options approved by the Board of Directors of Revenio Group Corporation on December 17, 2020, have been entered into the trade register today. The share subscription price under 2015C option rights was 12.48 EUR per share. The subscription period for 2015C options is May 31, 2019 – May 31, 2021.
After these subscriptions, the number of Revenio Group Corporation's shares and votes will rise to 26,658,952. The subscription price of the shares is recorded in their entirety in the reserve for invested unrestricted equity.
Revenio Group Corporation has applied for the listing of its new shares on the Nasdaq Helsinki in the same series as the company's existing shares. According to the current estimate, the new shares will be listed on December 30, 2020.
Revenio Group Corporation Board of Directors
Jouni Toijala, CEO, tel. +358 50 484 0085 [email protected] www.revenio.fi
Revenio is a health tech group operating on the international market and a global leader in ophthalmological devices. Revenio Group's ophthalmic diagnostic solutions include intraocular pressure measurement devices under the iCare brand, retinal imaging devices and perimeters. The main tools for the detection and diagnosis of glaucoma and its monitoring during treatment are intraocular pressure measurement (tonometry), retinal imaging, and visual field tests (perimetry).
The Revenio Group comprises Revenio Group Oyj, Icare Finland Oy, Icare USA Inc., Revenio Italy S. R. L, CenterVue SpA, Revenio Research Oy, Done Medical Oy and Oscare Medical Oy.
In 2019, the Group's net sales totaled EUR 49.5 million, with its operating profit standing at 25.5%. Revenio Group Corporation is listed on Nasdaq Helsinki with the trading code REG1V.
Revenio Group Corporation: Increased number of shares entered into trade register
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.